Petros Pharmaceuticals Inc (NASDAQ:PTPI)’s traded shares stood at 18.43 million during the last session, with the company’s beta value hitting 2.20. At the close of trading, the stock’s price was $0.27, to imply a decrease of -10.00% or -$0.03 in intraday trading. The PTPI share’s 52-week high remains $19.16, putting it -6996.3% down since that peak but still an impressive 3.7% since price per share fell to its 52-week low of $0.26. The company has a valuation of $0.58M, with an average of 8.38 million shares in intraday trading volume over the past 10 days and average of 2.35 million shares over the past 3 months.

Petros Pharmaceuticals Inc (NASDAQ:PTPI) trade information

After registering a -10.00% downside in the last session, Petros Pharmaceuticals Inc (PTPI) has traded red over the past five days. The 5-day price performance for the stock is -78.91%, and -87.14% over 30 days. With these gigs, the year-to-date price performance is -97.26%. Short interest in Petros Pharmaceuticals Inc (NASDAQ:PTPI) saw shorts transact 0.12 million shares and set a 0.08 days time to cover.

PTPI Dividends

Petros Pharmaceuticals Inc has its next earnings report out on 2024-Nov-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

We also have VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Petros Pharmaceuticals Inc (PTPI) shares. Going by data provided on Dec 31, 2024 , VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund holds roughly 31.81 shares. This is just over 0.06% of the total shares, with a market valuation of $8588.0. Data from the same date shows that the other fund manager holds a little less at 34.65, or 0.06% of the shares, all valued at about 9354.0.